Project Grant R21CA292343
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $388K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...
- This $744,575 project grant was awarded on May 16, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant is funding research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells and its role in the development of high-grade serous ovarian cancer (HGSOC). The research involves...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore (UMB) to conduct research on the mechanisms by which chemotherapy can inadvertently promote metastasis in epithelial ovarian cancer. The research aims to determine how clinically approved chemotherapies activate tumor-associated membrane-anchored serine proteases (MASPs) in a way that potentiates tumor dissemination and metastatic...
- This federal Project Grant award of $412,429.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research at the Mayo Clinic to investigate novel approaches for treating high-grade serous ovarian cancer (HGSOC). The research aims to evaluate how the nuclear translocation of cathepsin L (NCTSL) can sensitize CCNE1-driven HGSOC tumors to combination therapies involving DNA-damaging agents and PARP inhibitors. Key objectives include...
- The University of Pittsburgh received a $180,632 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on halting breast cancer metastasis. The project aims to discover and validate compounds that can block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this process has been linked to increased tumor growth, metastasis, and chemotherapy resistance. Using microfluidic technology, the researchers will create a...
- This Project Grant award of $176,712.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh, supports research on immunosurveillance mechanisms that eliminate pre-cancerous cells prior to the formation of malignancies. The primary objective is to investigate how tumor-derived heat shock proteins (HSPs) engage the CD91 receptor on antigen-presenting cells, leading to priming of T cell responses against emerging tumors. This research...
- This $563,233 Project Grant was awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Medical University of South Carolina on April 1, 2025. The grant funds research aimed at understanding how the sphingosine kinase 2 (SPHK2) enzyme and its product sphingosine 1-phosphate (S1P) regulate the suppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. Specifically, the research seeks to determine how SPHK2-mediated S1P induces...
- This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- The federal Project Grant award of $457,185.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a research project led by Clemson University to characterize fallopian tube-derived extracellular vesicles for the discovery of ovarian cancer biomarkers. The 2-year project, running from July 1, 2024 to June 30, 2026, will leverage Clemson University's expertise in areas like cancer research, biomedical engineering, and...